Han P, Han ZQ, Mao X, Wang J, Li QL, Xiao M, Meng L, Tian DA, Hong ZY. Liver cancer concurrent with chronic myelocytic leukemia and extreme thrombocytosis: a rare case report.
J Int Med Res 2022;
50:3000605221123684. [PMID:
36151757 PMCID:
PMC9513580 DOI:
10.1177/03000605221123684]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Chronic myelocytic leukemia (CML) can occasionally occur after long-term
chemotherapy for solid tumors; solid tumors secondary to chemotherapy and
biotherapy for CML have also been reported. However, concurrence of these two
phenomena in an untreated patient has seldom been reported. Herein, we describe
the case of a female patient in her early 60 s who was transferred to the liver
surgery department after the discovery of a large liver mass and elevated plasma
alpha-fetoprotein levels. She was initially diagnosed with liver cancer. Blood
tests indicated an increased platelet count (2464 × 109/L).
Chromosomal examination from a bone marrow biopsy indicated the presence of the
t(9;22) translocation, and subsequent fluorescence in situ
hybridization and PCR were positive for the BCR-ABL rearrangement. A diagnosis
of CML was made. The patient received hydroxyurea and imatinib to treat CML and
underwent subsequent platelet-lowering therapy and a liver biopsy, which
suggested moderately poorly differentiated adenocarcinoma or potentially hepatic
metastatic carcinoma. However, the patient refused further pathological
examination or screening for the site of the primary tumor. She died 6.5 months
after discharge. The exact relationship between the two tumors remains unclear,
and more patients need to be evaluated.
Collapse